BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• BioMidwest

  ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study

  Zivo Bioscience, Inc. announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics.

  February 7, 2024

   · 

  5 min read
• Drug Development

  New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

  Protagonist Therapeutics, Inc. (NASDAQ:PTGX) (“Protagonist” or the “Company”) today announced publication in the New England Journal of Medicine (NEJM) of the Phase 2b FRONTIER 1 trial evaluating JNJ-2113 in adults living with moderate-to-severe plaque psoriasis (PsO).

  February 7, 2024

   · 

  9 min read
• Deals

  Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

  Kyverna Therapeutics, Inc. announced the pricing of its upsized initial public offering of 14,500,000 shares of its common stock at an initial public offering price of $22.00 per share.

  February 7, 2024

   · 

  4 min read